Recommendations for treating patients with Gaucher disease with emerging enzyme products

Blood Cells, Molecules, and Diseases

Volumn 44, Issue 2, 2010, Pages 84-85

  Cox, Timothy M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDASE; IMIGLUCERASE; RECOMBINANT ENZYME; TALIGLUCERASE ALFA; UNCLASSIFIED DRUG; VELAGLUCERASE ALFA;

CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE REDUCTION; GAUCHER DISEASE; HEALTH CARE ACCESS; HIGH RISK PATIENT; HUMAN; LETTER; PATIENT IDENTIFICATION; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESOURCE MANAGEMENT;

CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; EUROPE; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEALTH PLANNING GUIDELINES; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 74849119650     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2009.12.001     Document Type: Letter

References (3)

1. European Medicines Agency (EMEA). Questions and answers on the shortages of Cerezyme and Fabrazyme. 14-8-2009.
2. Hollak C.E.M., et al. Force Majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol. Dis. (2009) Oct 3. [Electronic publication ahead of print]
3. European Medicines Agency (EMEA) Updated temporary treatment recommendations for Cerezyme. Doc. Ref. EMEA/665112/2009 22-10-2009.